

## **ABSTRACTS**

# HARMONY Alliance research results and presentations

### SATURDAY - DECEMBER 10, 2022



Oral: Rearrangements Involving 11q23/KMT2A: Mutational Landscape and Prognostic Implications – Results of the Harmony Alliance AML Database Alberto Hernández, University Hospital of Salamanca

- Session Name: 617. Acute Myeloid Leukemias: Biomarkers, Molecular Markers and Minimal Residual Disease in Diagnosis and Prognosis: Genomic Lesions and Therapeutic Implications
- Session Time: 02:00 PM 03:30 PMPresentation Time: 03:00 PM
- Room: Ernest N. Morial Convention Center, 291-292
- Publication Number: 227Submission ID: 167480
- https://ash.confex.com/ash/2022/webprogram/Paper167480.html





Oral: Machine Learning Allows the Identification of New Co-Mutational Patterns with Prognostic Implications in NPM1 Mutated AML – Results of the European Harmony Alliance

Alberto Hernández, University Hospital of Salamanca

- Session Name: 617. Acute Myeloid Leukemias: Biomarkers, Molecular Markers and Minimal Residual Disease in Diagnosis and Prognosis: Molecular Features and Response to Treatment in AML
- Session Time: 04:00 PM 05:30 PM
- Presentation Time: 04:45 PM
- Room: Ernest N. Morial Convention Center, 388-390
- Publication Number: 304
- Submission ID: 167138
- https://ash.confex.com/ash/2022/webprogram/Paper167138.html



#### SATURDAY - DECEMBER 10, 2022



Poster: Pan-Stakeholder Core Outcome Set (COS) definition for Hematological Malignancies within the framework of HARMONY and **HARMONY PLUS projects** 

Katharina Lang, Charité Universitätsmedizin Berlin

Session Name: 906. Outcomes Research—Myeloid Malignancies: Poster I

Presentation Time: 05:30 PM - 07:30 PM

Location: Ernest N. Morial Convention Center, Hall D

 Publication Number: 2316 Submission ID: 157549

https://ash.confex.com/ash/2022/webprogram/Paper157549.html



#### SUNDAY - DECEMBER 11, 2022



Poster: Long-term follow-up of AML patients treated intensively before the era of targeted agents - A big data analysis from the HARMONY collaboration

Marta Sobas, Medical University of Wroclaw

Session Name: 613. Acute Myeloid Leukemias: Clinical and Epidemiological: Poster II

- Presentation Time: 06:00 PM - 08:00 PM

Location: Frnest N. Morial Convention Center, Hall D.

 Publication Number: 2697 Submission ID: 165088

https://ash.confex.com/ash/2022/webprogram/Paper165088.html





Poster: Robust validation of the UKALL high hyperdiploid risk profile using individual patient data collected by the HARMONY alliance Anthony Moorman, University of Newcastle

 Session Name: 618. Acute Lymphoblastic Leukemias: Biomarkers, Molecular Markers and Minimal Residual Disease in Diagnosis and Prognosis: Poster II

Presentation Time: 06:00 PM - 08:00 PM

Location: Ernest N. Morial Convention Center, Hall D.

 Publication Number: 2834 Submission ID: 157680

https://ash.confex.com/ash/2022/webprogram/Paper157680.html





Poster: IKZF1 Deletions Are Markers of Treatment Resistance in Adult Ph-Negative B-Cell Acute Lymphoblastic Leukemia Patients Treated within the Ongoing Risk-Adapted Pethema LAL19 Trial

Jordi Ribera, IJC Josep Carreras Leukaemia Research Institute

 Session Name: 618. Acute Lymphoblastic Leukemias: Biomarkers, Molecular Markers and Minimal Residual Disease in Diagnosis and Prognosis: Poster II

Presentation Time: 06:00 PM - 08:00 PM

Location: Ernest N. Morial Convention Center, Hall D

Number: 2822

https://ash.confex.com/ash/2022/webprogram/Paper162159.html

